摘要
目的:观察氨磺必利治疗残留型精神分裂症的临床效果。方法:选取62例残留型精神分裂症患者作为研究对象,随机分为观察组和对照组各31例,对照组给予氯氮平治疗,观察组给予氨磺必利治疗,比较两组治疗前后阳性和阴性症状量表(PANSS)评分、临床疗效及不良反应发生率。结果:治疗后,观察组PANSS评分明显低于对照组,差异有统计学意义(P<0.05);观察组治疗总有效率为93.55%,显著高于对照组的83.87%,差异有统计学意义(P<0.05);观察组不良反应发生率为29.03%,显著低于对照组的41.94%,差异有统计学意义(P<0.05)。结论:与氯氮平相比,氨磺必利治疗残留型精神分裂症的效果更理想,可明显改善患者的临床症状,且安全性高。
Objective:To observe clinical effects of Amisulpride in treatment of residual schizophrenia.Methods:Sixty-two patients with residual schizophrenia were selected as the research objects and randomly divided into observation group and control group,31 cased in each group.The control group was given Clozapine,while the observation group was given Amisulpride.The positive and negative symptoms scale(PANSS)scores,clinical efficacy,and incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After the treatment,the PANSS score in the observation group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).The total effective rate in the observation group was 93.55%,which was significantly higher than 83.87%in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 29.03%,which was significantly lower than the control group of 41.94%,and the difference was statistically significant(P<0.05).Conclusions:Compared with Clozapine,Amisulpride is more effective and safe in the treatment of residual schizophrenia.
作者
蒋卫平
JIANG Weiping(Xuzhou Guangci Hospital,Xuzhou 221400 Jiangsu,China)
出处
《中国民康医学》
2020年第1期87-88,92,共3页
Medical Journal of Chinese People’s Health
